Analysts Set Sanofi (NASDAQ:SNY) PT at $62.67

Shares of Sanofi (NASDAQ:SNY) have been assigned a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $62.6667.

Several equities analysts have weighed in on SNY shares. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Barclays downgraded Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Citigroup started coverage on Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, Wall Street Zen upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st.

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently modified their holdings of the company. CreativeOne Wealth LLC increased its position in Sanofi by 8.3% in the 4th quarter. CreativeOne Wealth LLC now owns 8,870 shares of the company’s stock worth $430,000 after purchasing an additional 683 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in Sanofi by 9.2% in the fourth quarter. Kestra Advisory Services LLC now owns 26,803 shares of the company’s stock worth $1,299,000 after buying an additional 2,261 shares during the last quarter. Transamerica Financial Advisors LLC increased its holdings in Sanofi by 18.2% in the fourth quarter. Transamerica Financial Advisors LLC now owns 9,466 shares of the company’s stock worth $459,000 after buying an additional 1,460 shares during the last quarter. Parkside Financial Bank & Trust raised its position in Sanofi by 9.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,315 shares of the company’s stock valued at $161,000 after acquiring an additional 278 shares in the last quarter. Finally, PCM Encore LLC acquired a new stake in Sanofi in the fourth quarter valued at approximately $422,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 2.2%

NASDAQ:SNY opened at $46.01 on Monday. The stock has a fifty day simple moving average of $47.73 and a 200 day simple moving average of $48.59. The firm has a market capitalization of $112.22 billion, a price-to-earnings ratio of 12.78, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Closed Dynavax acquisition bolsters Sanofi’s adult vaccine portfolio — a strategic, revenue‑adding move that supports longer‑term vaccine growth. Sanofi Closes Dynavax Acquisition to Bolster Adult Vaccine Portfolio
• Neutral Sentiment: Sanofi issued official press materials confirming Belén Garijo will become CEO after the board decided not to renew Paul Hudson’s mandate — a formal transition that reduces short‑term uncertainty about leadership succession. Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
• Neutral Sentiment: Profiles and coverage detail Garijo’s background (ex‑Merck KGaA) and the board’s decision — helpful context for assessing whether she can execute a turnaround. Who is Sanofi’s new CEO Belén Garijo?
• Negative Sentiment: Market reaction: multiple outlets report a sell‑off and the stock trading near 52‑week lows as investors worry the leadership change reflects deeper pipeline and execution problems. Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors
• Negative Sentiment: Analyst reaction: Bank of America downgraded Sanofi from Buy to Neutral, increasing near‑term downside pressure from institutional holders. Sanofi downgraded by Bank of America
• Negative Sentiment: Investor concerns about the drug pipeline and U.S. vaccine sentiment under the current administration add execution risk for the incoming CEO — Reuters highlights that Garijo must accelerate R&D and navigate political headwinds. Sanofi’s new CEO needs to fix drug pipeline and navigate Trump
• Negative Sentiment: News summaries and headlines emphasize the abrupt ousting of Paul Hudson, which has amplified investor uncertainty and short‑term selling. SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.